Altimmune Inc - Understand $alt stock

$ALT Market Cap: $528.1 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$409.0K

TTM

Gross Margin

Net Earnings

-$101.3M

TTM

Current Assets

$171.2M

Q2 2024

Current Liabilities

$15.16M

Q2 2024

Current Ratio

1129.57%

Q2 2024

Total Assets

$173.3M

Q2 2024

Total Liabilities

$20.82M

Q2 2024

Book Value

$152.5M

Q2 2024

Cash

$57.13M

Q2 2024

P/E

-5.210

Sep 18, 2024 EST

Free Cash Flow

-$37.02M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	$426.0K	-$68.00K	$4.410M	$8.185M	$5.800M	$10.33M	$10.74M	$3.236M	$10.64M	$10.19M	$17.91M	$25.18M	$24.27M	$20.99M	$27.55M	$32.91M	$14.64M	$1.660M	$590.0K
YoY Change	-726.47%	-101.54%	-46.12%	41.12%	-43.86%	-3.79%	231.82%	-69.58%	4.42%	-43.1%	-28.87%	3.75%	15.63%	-23.81%	-16.29%	124.8%	781.93%	181.36%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	$426.0K	-$68.00K	$4.410M	$8.185M	$5.800M	$10.33M	$10.74M	$3.236M	$10.64M	$10.19M	$17.91M	$25.18M	$24.27M	$20.99M	$27.55M	$32.91M	$14.64M	$1.660M	$590.0K
Cost Of Revenue									-$50.00K
Gross Profit									$10.69M
Gross Profit Margin									100.47%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Selling, General & Admin	$18.14M	$17.13M	$15.41M	$13.21M	$8.500M	$9.770M	$8.460M	$7.110M	$6.220M	$10.91M	$13.28M	$11.63M	$14.31M	$18.02M	$22.43M	$19.40M	$13.88M	$8.450M	$260.0K
YoY Change	5.85%	11.16%	16.68%	55.41%	-13.0%	15.48%	18.99%	14.31%	-42.99%	-17.85%	14.19%	-18.73%	-20.59%	-19.66%	15.62%	39.77%	64.26%	3150.0%
% of Gross Profit									58.19%
Research & Development	$65.80M	$70.54M	$74.54M	$49.77M	$6.541M	$18.38M	$18.41M	$7.221M	$5.134M	$9.320M	$15.29M	$19.51M	$21.22M	$20.88M	$30.22M	$31.81M	$16.56M	$7.260M
YoY Change	-6.72%	-5.37%	49.76%	660.9%	-64.41%	-0.14%	154.88%	40.67%	-44.92%	-39.05%	-21.63%	-8.06%	1.65%	-30.92%	-5.0%	92.09%	128.1%
% of Gross Profit									48.02%
Depreciation & Amortization	$477.0K	$500.0K	$551.3K	$428.9K	$387.3K	$218.7K	$83.83K	$63.11K	$141.6K	$150.0K	$182.5K	$303.9K	$461.1K	$1.020M	$870.0K	$810.0K	$660.0K	$480.0K
YoY Change	-4.6%	-9.31%	28.54%	10.73%	77.09%	160.89%	32.84%	-55.43%	-5.57%	-17.83%	-39.95%	-34.09%	-54.8%	17.24%	7.41%	22.73%	37.5%
% of Gross Profit									1.32%
Operating Expenses	$83.94M	$87.67M	$101.3M	$62.98M	$6.541M	$28.23M	$62.78M	$14.33M	$14.04M	$20.38M	$28.75M	$31.44M	$35.99M	$44.55M	$53.52M	$52.03M	$31.15M	$16.20M	$260.0K
YoY Change	-4.26%	-13.47%	60.87%	862.84%	-76.83%	-55.04%	338.19%	2.02%	-31.1%	-29.11%	-8.56%	-12.64%	-19.2%	-16.77%	2.86%	67.03%	92.28%	6130.77%
Operating Profit	-$95.93M	-$87.74M	-$96.91M	-$54.80M	-$21.46M		-$52.05M	-$11.09M	-$3.403M	-$10.19M	-$10.84M	-$6.266M	-$11.73M	-$23.55M
YoY Change	9.33%	-9.47%	76.85%	155.29%			369.23%	225.96%	-66.61%	-5.98%	72.97%	-46.56%	-50.22%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Interest Expense	$7.316M	$8.000K	$5.656K	$9.421K	$2.244K	$297.1K	$162.1K	$38.50K	$54.58K	$210.4K	$366.7K	$324.8K	$54.57K	$5.936M	-$1.520M	-$1.230M	$2.030M	-$600.0K
YoY Change	91350.0%	41.44%	-39.96%	319.83%	-99.24%	83.23%	321.15%	-29.46%	-74.06%	-42.62%	12.92%	495.08%	-99.08%	-490.56%	23.58%	-160.59%	-438.33%
% of Operating Profit
Other Income/Expense, Net	$166.0K	$2.830M	-$176.8K	$337.2K	$886.3K	-$2.487M	-$18.51K	$4.851K	$23.84K	$297.7K	-$817.4K	$1.542M	$7.928M	-$11.30M	-$90.00K	$60.00K	$0.00
YoY Change	-94.13%	-1700.83%	-152.42%	-61.95%	-135.64%	13336.38%	-481.49%	-79.65%	-91.99%	-136.42%	-153.02%	-80.55%	-170.19%	12450.8%	-250.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Pretax Income	-$88.45M	-$84.91M	-$97.09M	-$54.46M	-$20.58M	-$45.32M	-$52.06M	-$11.09M	-$3.379M	-$9.894M	-$11.66M	-$4.725M	-$3.798M	-$34.85M	-$32.28M	-$36.42M	-$13.59M	-$15.13M	$330.0K
YoY Change	4.17%	-12.55%	78.27%	164.65%	-54.59%	-12.95%	369.6%	228.11%	-65.85%	-15.12%	146.72%	24.41%	-89.1%	7.96%	-11.37%	167.99%	-10.18%	-4684.85%
Income Tax	$0.00	-$197.0K	$0.00	-$5.417M	-$58.50K	-$6.150M	-$5.638M	$0.00	$61.75K	$61.75K	$61.75K	$195.5K			$0.00	$0.00	$0.00	$0.00	$50.00K
% Of Pretax Income																			15.15%
Net Earnings	-$88.45M	-$84.71M	-$97.09M	-$49.04M	-$20.52M	-$39.17M	-$46.43M	-$11.09M	-$3.441M	-$9.955M	-$11.72M	-$4.920M	-$3.798M	-$34.85M	-$32.28M	-$36.42M	-$13.59M	-$15.13M	$280.0K
YoY Change	4.41%	-12.75%	97.96%	139.01%	-47.61%	-15.63%	318.74%	222.23%	-65.44%	-15.04%	138.17%	29.56%	-89.1%	7.96%	-11.37%	167.99%	-10.18%	-5503.57%
Net Earnings / Revenue	-20762.21%		-2201.43%	-599.2%	-353.8%	-379.16%	-432.33%	-342.59%	-32.34%	-97.7%	-65.43%	-19.54%	-15.65%	-166.03%	-117.17%	-110.67%	-92.83%	-911.45%	47.46%
Basic Earnings Per Share	-$1.66	-$1.81	-$2.35	-$1.91				$2.97	-$0.05	-$0.17
Diluted Earnings Per Share	-$1.66	-$1.81	-$2.35	-$1.91	-$1.564M	-$13.99M	-$108.0M	$2.95	-$0.05	-$0.17	-$68.94M	-$30.75M	-$23.75M	-$316.8M	-$358.7M	-$455.3M	-$453.0M	-$11.48B	$200.6M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Cash & Short-Term Investments	$197.8M	$184.9M	$190.3M	$215.9M	$37.20M	$33.70M	$8.800M	$2.900M	$15.60M	$18.60M	$10.50M	$12.70M	$11.20M	$11.80M	$5.800M	$22.90M	$52.70M	$5.100M	$1.400M
YoY Change	7.0%	-2.85%	-11.86%	480.38%	10.39%	282.95%	203.45%	-81.41%	-16.13%	77.14%	-17.32%	13.39%	-5.08%	103.45%	-74.67%	-56.55%	933.33%	264.29%
Cash & Equivalents	$135.1M	$111.1M	$190.3M	$115.9M	$9.000M	$33.70M	$8.800M	$2.900M	$9.100M	$12.20M	$10.50M	$12.70M	$11.20M	$11.80M	$2.700M	$19.80M	$40.60M	$5.100M	$1.400M
Short-Term Investments	$62.70M	$73.78M	$0.00	$100.0M	$28.30M				$6.400M	$6.400M					$3.100M	$3.200M	$12.20M	$0.00
Other Short-Term Assets	$6.958M	$5.392M	$7.987M	$1.900M	$500.0K	$1.100M	$4.500M	$400.0K	$200.0K	$200.0K	$200.0K	$500.0K	$900.0K	$2.500M	$1.000M	$12.90M	$500.0K	$1.000M	$68.70M
YoY Change	29.04%	-32.49%	320.36%	280.0%	-54.55%	-75.56%	1025.0%	100.0%	0.0%	0.0%	-60.0%	-44.44%	-64.0%	150.0%	-92.25%	2480.0%	-50.0%	-98.54%
Inventory
Prepaid Expenses
Receivables	$1.111M	$173.0K	$428.8K	$4.600M	$1.000M	$3.500M	$3.800M	$400.0K	$1.500M	$400.0K	$3.600M	$6.500M	$7.400M	$9.300M	$8.900M	$3.800M	$4.000M	$1.500M
Other Receivables	$3.742M	$2.368M	$5.410M	$7.800M	$700.0K	$1.000M	$6.400M	$800.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$9.800M	$6.500M	$1.200M	$0.00
Total Short-Term Assets	$209.6M	$192.8M	$204.1M	$230.3M	$39.40M	$39.40M	$23.50M	$4.500M	$17.20M	$19.30M	$14.30M	$19.80M	$19.60M	$23.60M	$25.50M	$46.10M	$58.50M	$7.600M	$70.10M
YoY Change	8.72%	-5.54%	-11.37%	484.52%	0.0%	67.66%	422.22%	-73.84%	-10.88%	34.97%	-27.78%	1.02%	-16.95%	-7.45%	-44.69%	-21.2%	669.74%	-89.16%
Property, Plant & Equipment	$1.014M	$1.677M	$2.246M	$2.000M	$1.800M	$1.300M	$600.0K	$200.0K	$200.0K	$300.0K	$400.0K	$500.0K	$800.0K	$1.200M	$6.300M	$5.300M	$6.600M	$5.200M
YoY Change	-39.53%	-25.33%	12.3%	11.11%	38.46%	116.67%	200.0%	0.0%	-33.33%	-25.0%	-20.0%	-37.5%	-33.33%	-80.95%	18.87%	-19.7%	26.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$19.00K	$73.80K	$100.0K	$100.0K	$200.0K	$200.0K	$0.00	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$300.0K	$1.500M	$300.0K	$700.0K
YoY Change		-74.25%	-26.2%	0.0%	-50.0%	0.0%		-100.0%	0.0%	0.0%	0.0%	0.0%	0.0%	-66.67%	-80.0%	400.0%	-57.14%
Total Long-Term Assets	$1.014M	$14.12M	$14.74M	$14.80M	$14.70M	$15.40M	$39.50M	$33.90M	$2.700M	$2.700M	$2.800M	$2.900M	$3.200M	$3.600M	$9.800M	$10.30M	$8.100M	$7.200M	$0.00
YoY Change	-92.82%	-4.23%	-0.41%	0.68%	-4.55%	-61.01%	16.52%	1155.56%	0.0%	-3.57%	-3.45%	-9.38%	-11.11%	-63.27%	-4.85%	27.16%	12.5%
Total Assets	$210.6M	$206.9M	$218.9M	$245.1M	$54.10M	$54.80M	$63.00M	$38.40M	$19.90M	$22.00M	$17.10M	$22.70M	$22.80M	$27.20M	$35.30M	$56.40M	$66.60M	$14.80M	$70.10M
YoY Change
Accounts Payable	$2.070M	$4.804M	$2.034M	$600.0K	$0.00	$400.0K	$100.0K	$2.000M	$500.0K	$400.0K	$1.100M	$1.700M	$1.400M	$3.100M	$1.900M	$3.900M	$1.400M	$800.0K	$0.00
YoY Change	-56.91%	136.13%	239.08%		-100.0%	300.0%	-95.0%	300.0%	25.0%	-63.64%	-35.29%	21.43%	-54.84%	63.16%	-51.28%	178.57%	75.0%
Accrued Expenses	$10.07M	$11.08M	$10.15M	$11.40M	$3.800M	$4.100M	$3.600M	$3.000M	$1.500M	$1.100M	$3.100M	$2.300M	$2.700M	$3.000M	$9.800M	$6.200M	$2.900M	$1.600M	$100.0K
YoY Change	-9.1%	9.16%	-10.95%	200.0%	-7.32%	13.89%	20.0%	100.0%	36.36%	-64.52%	34.78%	-14.81%	-10.0%	-69.39%	58.06%	113.79%	81.25%	1500.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$500.0K	$0.00	$0.00	$1.100M	$1.300M	$0.00	$0.00	$0.00	$13.40M	$0.00	$11.80M	$0.00
YoY Change							-100.0%			-100.0%	-15.38%				-100.0%		-100.0%
Long-Term Debt Due					$0.00	$100.0K			$0.00	$700.0K	$1.000M	$800.0K	$0.00			$4.000M	$4.000M	$0.00
YoY Change					-100.0%				-100.0%	-30.0%	25.0%					0.0%
Total Short-Term Liabilities	$12.14M	$17.05M	$18.28M	$12.00M	$3.900M	$4.500M	$3.800M	$5.500M	$2.200M	$2.600M	$6.800M	$7.500M	$4.600M	$6.200M	$13.50M	$35.90M	$9.000M	$14.20M	$400.0K
YoY Change	-28.8%	-6.69%	52.3%	207.69%	-13.33%	18.42%	-30.91%	150.0%	-15.38%	-61.76%	-9.33%	63.04%	-25.81%	-54.07%	-62.4%	298.89%	-36.62%	3450.0%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$500.0K	$600.0K	$500.0K	$0.00	$0.00	$700.0K	$1.700M	$0.00	$0.00	$17.40M	$900.0K	$16.70M	$0.00	$0.00
YoY Change					-100.0%	-16.67%	20.0%			-100.0%	-58.82%			-100.0%	1833.33%	-94.61%
Other Long-Term Liabilities	$4.398M	$4.581M	$1.454M	$7.200M	$4.600M	$1.400M	$4.000M	$200.0K	$1.000M	$1.100M	$2.300M	$1.900M	$2.300M	$8.800M	$1.300M	$600.0K	$400.0K	$2.400M
YoY Change	-3.99%	215.02%	-79.8%	56.52%	228.57%	-65.0%	1900.0%	-80.0%	-9.09%	-52.17%	21.05%	-17.39%	-73.86%	576.92%	116.67%	50.0%	-83.33%
Total Long-Term Liabilities	$4.398M	$4.581M	$1.454M	$7.200M	$4.600M	$1.900M	$4.600M	$700.0K	$1.000M	$1.100M	$3.000M	$3.600M	$2.300M	$8.800M	$18.70M	$1.500M	$17.10M	$2.400M	$0.00
YoY Change	-3.99%	215.02%	-79.8%	56.52%	142.11%	-58.7%	557.14%	-30.0%	-9.09%	-63.33%	-16.67%	56.52%	-73.86%	-52.94%	1146.67%	-91.23%	612.5%
Total Liabilities	$16.54M	$21.64M	$19.73M	$19.20M	$8.500M	$6.400M	$14.40M	$6.200M	$3.200M	$3.700M	$9.800M	$11.10M	$7.000M	$15.00M	$32.20M	$37.40M	$26.00M	$19.20M	$400.0K
YoY Change	-23.55%	9.65%	2.76%	125.88%	32.81%	-55.56%	132.26%	93.75%	-13.51%	-62.24%	-11.71%	58.57%	-53.33%	-53.42%	-13.9%	43.85%	35.42%	4700.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2016	2015	2014
Basic Shares Outstanding	53.25M	46.93M	41.28M	25.64M	65.31M shares	63.99M shares	57.54M shares
Diluted Shares Outstanding	53.25M	46.93M	41.28M	25.64M	65.66M shares	63.99M shares	57.54M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $528.06 Million

About Altimmune Inc

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The company is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The firm has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Industry: Pharmaceutical Preparations Peers: Agenus Inc Cullinan Therapeutics Inc Hillevax Inc IDEAYA Biosciences Inc Inhibrx, Inc. Mersana Therapeutics Inc Nurix Therapeutics Inc Nkarta Inc Vera Therapeutics Inc